The Impact of Active Nurse Participation on Adenoma Detection During Routine Colonoscopy

This study has been completed.
Information provided by (Responsible Party):
Harry Aslanian, Yale University Identifier:
First received: March 10, 2009
Last updated: January 20, 2015
Last verified: January 2015

Hypothesis-- Nurse observation in addition to the colonoscopist while withdrawing the colonoscope from the cecum leads to a greater adenoma detection rate.

Methods- Patients presenting for screening colonoscopy are randomized to nurse observation or usual practice. Risk factors for adenoma development and the adenoma detection rate in each group will be evaluated.

Condition Intervention
Procedure: nurse observation during colonoscope withdrawal

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: The Impact of Active Nurse Participation on Adenoma Detection During Routine Colonoscopy

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Adenoma detection rate [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 500
Study Start Date: November 2008
Study Completion Date: January 2015
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Nurse participation during colonoscope withdrawal
Procedure: nurse observation during colonoscope withdrawal
nurse observation during colonoscope withdrawal
No Intervention: 2
usual colonoscopy practice


Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • performance of screening colonoscopy

Exclusion Criteria:

  • history of inflammatory bowel disease, gastrointestinal bleeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00859625

United States, Connecticut
Yale-New Haven Hospital
New Haven, Connecticut, United States, 06520
Sponsors and Collaborators
Yale University
Principal Investigator: Harry Aslanian, MD Yale University
  More Information

Responsible Party: Harry Aslanian, Associate Professor, Yale University Identifier: NCT00859625     History of Changes
Other Study ID Numbers: HIC0809004192 
Study First Received: March 10, 2009
Last Updated: January 20, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Yale University:
adenoma detection rate

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial processed this record on May 22, 2016